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Background: Recent advancement in both human embryology and preimplantation genetic screening has created
a completely new situation for human assisted reproduction. Embryos, typically at blastocyst stage, are biopsied
and screened by DNA microarray or next-generation sequencing before cryopreservation, and then euploid embryos
are warmed for transfer. Increased embryo implantation rates have been reported after transfer of euploid embryos
screened for all chromosomes. However, some patients may have frozen their embryos without doing embryo biopsy
and screening, thus embryo biopsy and screening may be required after cryopreservation and warming. Such
procedures have not been performed routinely in clinics and the efficiency is still unknown. Therefore, in this
study, we investigated embryo implantation after blastocysts were cryopreserved/warmed, and then biopsied
and screened by DNA microarray for all chromosomes.
Results: Two hundred and thirty four cryopreserved blastocysts from 35 women were warmed, and 224 (95.7 %)
survived and were biopsied for aneuploidy screening. After analysis, 221 samples (98.7 %) had diagnostic results
and 3 (1.3 %) samples did not have results due to DNA quality and quantity. Out of the samples with diagnostic
results, 59.3 % were normal euploid and 40.7 % had abnormal chromosomes including aneuploidy, partial chromosome
deletion and/or duplication. Most (65.6 %) samples had single chromosome anomalies, and 34.4 % of the samples had
multiple chromosome anomalies. Chromosomal errors were observed in most chromosomes but chromosomes 21 and
22 had the most frequent chromosome anomalies. Transfer of 61 normal euploid blastocysts in 34 patients resulted in a
52.9 % clinical pregnancy rate and a 42.6 % implantation rate, and 41.2 % of the patients delivered normal babies or had
ongoing pregnancy.
Conclusions: Frozen blastocysts can be warmed and biopsied for aneuploidy screening. These results may suggest that
cryopreserved blastocysts can be warmed, biopsied and screened the day before embryo transfer, and such procedures
may benefit patients who had previous implantation failures, or patients who did not have embryo screening before
cryopreservation due to lack of embryo screening technology or other reasons.
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There are many reasons for patients to cryopreserve
their embryos after in vitro fertilization (IVF), such as
high risk of ovarian stimulation, endometrial develop-
ment unsynchronized with the embryos, elevated proges-
terone and surplus embryos after transfer. Recently, due
to application of preimplantation genetic screening (PGS)* Correspondence: wangweihua11@yahoo.com
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technology: vitrification [3, 4], indicating that cryopreser-
vation of human blastocysts by vitrification has caused
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PGS by transferring normal euploid embryos [5, 6]. It is
well known that women of advanced maternal age have
a high risk of producing aneuploid embryos, resulting in
implantation failure, a higher risk of miscarriage or birth
defects [7–9]. It has been found that PGS especially
benefits women with previous IVF failure(s), repeated
miscarriages, and those of advanced maternal ages
[10–12]. Blastocyst biopsy for PGS is thought be to the
most efficient approach as multiple cells are biopsied
from trophectoderm (TE) cells, which provides more
accurate results as compared to cleavage stage embryo
biopsy or polar body biopsy before and after egg
fertilization [13–15].
Practically, most patients request biopsy and PGS
before they start IVF cycles, thus embryos (blastocysts)
are biopsied before cryopreservation. This is the most
common procedure for PGS. However, some patients
may request the biopsy and PGS after embryo cryo-
preservation. These patients include 1) young patients
who thought that PGS was not necessary for them
during a fresh IVF cycle but whose embryo implantation
failed after fresh embryo transfer(s); 2) no PGS pro-
cedure was provided in the previous IVF cycles, so pa-
tients’ embryos were cryopreserved without biopsy
and PGS; 3) patients’ IVF cycles were performed a few
years ago (3 years ago or up to 30 years ago) and PGS
by aCGH or NGS was not available at that time. For
these reasons, some patients may request biopsy and
PGS on their cryopreserved embryos before frozen
embryo transfer (FET) allowing the patients to have
normal embryos for transfer. Recently, we found that
increased numbers of patients requested PGS for their
frozen embryos. Although embryo biopsy has been
applied to fresh blastocysts for a few years, it has not
been evaluated in frozen blastocysts. No data is avail-
able about TE biopsy for PGS after blastocysts are
cryopreserved and warmed. Therefore, in the present
study, we evaluated the efficiency of biopsy and PGS
of frozen/warmed human blastocysts by examining
clinical pregnancy and embryo implantation rates.
Methods
Ethics
Patients undergoing IVF, and PGS signed written con-
sents for all kinds of laboratory and clinical procedures.
The data was retrospectively collected from the medical
records and the study was approved by Institutional
Review Board (NEIRB 14-504).
Vitrification and warming
Blastocysts were vitrified by using Irvine vitrification
kit described as a previous method [16, 17]. Briefly, all
blastocysts were equilibrated in a warmed equilibrationsolution on a warming stage (37 °C) for 2 min, then
transferred into a warmed vitrification solution and
then loaded onto a vitrification straw between 40–60 s
before vitrification in liquid nitrogen. The blastocysts
were stored in the liquid nitrogen for at least one
month.
Blastocysts were warmed in the morning one day
before scheduled FET. Vitrified blastocysts were taken
out of liquid nitrogen, and the straw tip with blasto-
cyst(s) was immersed into 1.0 M warmed (37 °C) sucrose
solution for 1 min, then blastocysts were transferred to
0.5 M sucrose solution at room temperature for 3 min
and finally to a basic solution (no sucrose) for 10 min
with a solution change after 5 min at room temperature.
After warming, blastocysts were cultured in Global medium
(IVFonline.com) supplemented with 10 % serum protein
substitute at 37 °C in a humidified atmosphere of 6.5 %
CO2, 5 % O2 and balanced nitrogen before biopsy.
Blastocyst quality was assessed by using standard as-
sessments developed by the Society of Assisted Repro-
ductive Technology [18].
Blastocyst biopsy
If the blastocysts survived after warming, they were
biopsied as per the following procedures (also showed
in Fig. 1):
Blastocysts were transferred from a culture dish to a
biopsy dish in which 20–30 μl drops of biopsy medium
were previously made and covered with tissue culture
oil. The dish was then moved to a warmed inverted
phase contrast microscope stage and the biopsy was per-
formed at × 400 magnification. For biopsy, the blastocyst
was held from left side (9 o’clock position) and a ~20 μm
hole was made in the zona pellucida on the right side
(3 o’clock position) using the ZILOS-tk™ laser system
at a medium pulse power. Typically, 2–3 pulses were
required to make the zona pellucida open completely.
Because blastocysts have a large perivitelline space
(Fig. 1) after warming, zona opening by laser rarely
damages the embryo proper.
After opening the zona pellucida, a biopsy pipette
(20 μm diameter) was inserted into the opening in the
zona and cells were aspirated from the blastocysts. After
a few cells were aspirated into the biopsy pipette, the
biopsy pipette was pulled outside of the zona and at the
same time, a laser (low power or medium power) was
used to cut the cell connection in the front of the tip of
biopsy pipette. Three to five pulses were necessary to
separate some cells from the embryo proper. Approxi-
mately 5 ~ 10 TE cells were biopsied from the embryos.
After biopsy of a maximum of 4 blastocysts each
time, the biopsy dish was moved to a workstation and
TE cells from each sample were individually transferred
into properly labeled microcentrifuge tubes containing
Fig. 1 Images of blastocyst biopsy after cryopreservation and warming.
Top image indicates the blastocyst before biopsy and bottom image
indicates blastocysts during biopsy
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proper was transferred to culture dishes after washing
with culture medium 3–5 times, and then the culture dish
was returned to the incubator for continuing culture until
the day (second day morning) for transfer. The biopsied
samples were then subjected to whole genome amplifi-
cation (WGA) for 24-chromosomal analysis by micro-
array [19, 20].
Sample amplification
For DNA extraction and fragmentation, TE cell samples
and negative controls were collected in 2 μl of PBS
buffer, lysed with 2 μl of SurePlex cell extraction buffer
and 5 μl of the SurePlex Extraction cocktail master mix
and then incubated at 75 °C for 10 min followed by fur-
ther incubation at 95 °C for 4 min. Genomic DNA
(gDNA) was randomly fragmented by adding 5 μl of
SurePlex Pre-amplification cocktail to the lysed biopsy
samples or to gDNA controls and the mixture was incu-
bated according to the following protocol: one cycle of
95 °C for 2 min, followed by 12 cycles of 95 °C for 15 s,15 °C for 50 s, 25 °C for 40 s, 35 °C for 30 s, 65 °C for
40 s and 75 °C for 40 s, followed by a hold at 4 °C.
Genomic DNA was amplified using the PicoPLEX
WGA Kit (NEB) according to the following thermal cy-
cler program: one cycle of 95 °C for 2 min, followed by
14 cycles of 95 °C for 15 s, 65 °C for 1 min and 75 °C for
1 min, followed by a hold at 4 °C. Successful amplifica-
tion was confirmed by electrophoresis of 5 μl of each
amplified sample plus 5 μl gel loading buffer on a 1.5 %
agarose TBE gel.
aCGH of gDNA
For aCGH, 13 μl of amplified samples were labeled with
Cy3 or Cy5 using SureTag DNA labeling kit and labeled
samples were combined and co-precipitated with COT
Human DNA in preparation for hybridization. Labelled
DNA was then resuspended in dextran sulphate hybri-
dization buffer and loaded onto SurePrint G3 human
CGH 8 × 60 K oligo microarrays following manufac-
turer’s protocol. Reference DNA (both male and female
were used) for array was obtained from Promega (Promega
Corporation, Madison, WI USA).
Labelled products were then hybridized to array slides.
After hybridization, array slides were washed to remove
unbound labelled DNA and scanned with SureScan
scanner at 3 μM to excite the hybridized fluorophores
read and store the resulting images of the hybridization.
Finally, scanned images were analyzed by Cytogenomics
2.7.8.0 software following manufacturer’s protocol.
Human Genome Build 19 (hg19) was used in the present
study.
Patient preparation for embryo transfer
All patients for embryo transfer received estradiol orally
and transvaginally. Intramuscular administration of pro-
gesterone oil was initiated after about 14 days of estra-
diol treatment. Endometrium thickness was measured
on the day of progesterone administration. After PGS, if
the patients had normal euploid blastocysts, embryo
transfer was performed on the sixth or seventh day of
progesterone administration and progesterone was con-
tinued until the first serum β-hCG test two weeks after
transfer. Aneuploid embryos were discarded after acquiring
consents from patients or re-vitrified with other remaining
euploid blastocysts. Ongoing pregnancies were supported
by continued estradiol and progesterone.
Pregnancy and live birth/ongoing rate assessment
Fourteen days after embryo transfer, pregnancy was
tested by a serum β-hCG assay. When the β-hCG
was > 5 mIU/mL the patients were regarded as having
a biochemical pregnancy. Four weeks after embryo trans-
fer, when a gestational sac and a heartbeat appeared ultra-
sonographically, the patients were diagnosed as having a
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were indicated as live birth or ongoing per embryo
transfers.
Results
As shown in Table 1, 234 blastocysts were warmed from 35
warming cycles including 17 patients at ages of ≤35 years
old (young patients), 16 patients at ages of ≥36 years old
(advanced maternal age) and 2 recipients using donated
eggs. All of these patients had previous embryo im-
plantation failures (1–4 times), so they decided to
screen their embryos before FET. Due to the limited
number of patients in these groups, statistical analysis
between groups was not performed, and the major ob-
jective was focused on the method assessment.
After warming, 224 (95.7 %) blastocysts survived and
then were biopsied. After aCGH, 3 (1.3 %) blastocysts
did not have test results due to fragmented DNA or low
amount of DNA, and 221 (98.7 %) samples had diagnostic
results. Out of these samples, 59.3 % were normal euploid
and 40.7 % had chromosomal anomalies, including aneu-
ploidies, partial chromosome deletion and/or duplication
(Table 2). As shown in Table 2, most samples (65.6 %) had
single chromosomal abnormalities, while 34.4 % samples
had multiple chromosomal errors, i.e. at least two chro-







No. of cases 17 16 2 35
No. of embryos warmed 121 98 15 234
No. (%) of embryos
survived
119 (98.3) 60 (91.8) 15 (100) 224 (95.7)
No. of embryos biopsied 119 90 15 224
No. (%) of samples
without test results
1 (0.8) 1 (1.1) 1 (6.7) 3
(1.3)
No. (%) of embryos
with test results
118 (99.2) 89 (98.8) 14 (93.3) 221 (98.7)
No. (%) of normal
embryos
72 (61.0) 51 (57.3) 8 (57.1) 131 (59.3)
No. (%) of abnormal
embryos
46 (38.9) 38 (42.7) 6 (42.9) 90 (40.7)
No. of transfer 17 15a 2 34
No. (%) of clinical
pregnancy
9 (52.9) 7 (46.7) 2 (100) 18 (52.9)
No. of delivery and
ongoing pregnancy
6 (35.3) 6 (40.0) 2 (100) 14 (41.2)
No. of embryos
transferred
32 25 4 61
No. (%) of embryos
implanted
13 (40.6) 10 (40.0) 3 (75.0) 26 (42.6)
aOne patient did not have transfer due to all abnormal embryosAs shown in Fig. 2, chromosome abnormalities were
observed in most chromosomes except chromosomes 11
and 12. Errors in chromosomes 21 and 22 were the most
frequent chromosome anomalies, followed by chromo-
somes 15, 16, 2, 7 and 19.
During the study period, 34 out of 35 patients had at
least one euploid blastocyst for transfer, and 52.9 %,
46.7 % and 100 % (2/2) of clinical pregnancy rates were
obtained in patients at ages of ≤ 35, ≥36 and those who
received donor eggs, respectively, with an overall 52.9 %
of pregnancy rate and 42.6 % of embryo implantation
rate. Eight patients delivered normal babies and six still
had ongoing pregnancy.
Discussion
The present study, for the first time, reported the effi-
ciency of frozen/warmed blastocyst biopsy for PGS. Our
data showed that frozen/warmed blastocyst biopsy can
be done within an hour after completion of warming,
and FET can be done within 24 h after warming if there
are normal embryos. Because biopsy and aCGH take
more than 12 h, FET was scheduled on the second day
after embryo warming and biopsy. If the analysis could
be done in a shorter time, FET could be scheduled on
the same day for the patients. However, based on our ex-
perience, it would appear that embryo quality was not
affected by extended culture up to 24 h. It has been re-
ported that transfer of frozen/warmed blastocysts after
overnight culture (less than 18 h) had similar implant-
ation rates as compared with transfer of blastocysts after
same day warming [16].
Usually blastocysts start to expand 2–3 h after comple-
tion of warming, and it may be easier to choose the loca-
tion for biopsy if blastocysts re-expand. However, this
would take more time from embryo warming to FET
and it may be unfavorable to blastocyst implantation.
From the results obtained in the present report, we
found that our method is practical. It is still not known
if biopsy of re-expanded blastocysts can further improve
clinical outcomes.
For the warmed blastocyst biopsy, it is not necessary
to warm all blastocysts if patients have many cryopre-
served embryos in order to avoid re-freezing spare blas-
tocysts after transfer. Although reports indicated that
refreezing human blastocysts did not further impair em-
bryo quality and implantation [19–22], repeated cryo-
preservation and warming may be not a good practice
for human IVF, as long term effects of refreezing/warm-
ing on human embryos are not clear. Only limited case
reports indicated that embryo survival was not affected
by these procedures [19]. Therefore, in order to avoid re-
peated freezing/warming, it may be necessary to warm a
limited number of embryos for biopsy and analysis. The
only concern of testing a limited number of blastocysts
Table 2 Chromosome distribution in abnormal embryos








No. of euploid with
deletion & duplication
Single abnormality 59 (65.6 %) 42 (71.2 %) 13 (22.0 %) 2 (3.4 %) 2 (3.4 %)
Multiple abnormalities 31 (34.4 %) 29 (93.6 %) 0 0 2 (6.5 %)
Total 90 71 (78.9 %) 13 (14.4 %) 2 (2.2 %) 4 (4.4 %)
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after analysis, thus embryo transfer has to be cancelled.
In the present study, some patients had all frozen blasto-
cysts warmed and analyzed while some patients had a
portion of blastocysts warmed and analyzed. As a result,
only one patient did not have a euploid embryo, so her
FET was cancelled, while all others had at least one
normal embryo for FET.
Another concern is that there are limited number of
good quality of normal blastocysts for transfer if a por-
tion of embryos are warmed and analyzed. Because some
euploid blastocysts may have fair or poor quality. It has
been found that embryo implantation is related to the
total available embryos for PGS, which would ensure
that there is at least one good blastocyst to be euploid
for transfer [23]. Morphology and euploid status are
the two most important factors affecting embryo im-
plantation. Several studies have shown that morphology
assessment alone to select embryos for transfer has
limited prediction capacity for embryo implantation, as
some high morphology score embryos may be aneuploid
[7, 24, 25], especially in patients of advanced maternal age.
Also, aneuploid embryos with good morphology may re-
sult in miscarriage. Therefore, high live birth rate shouldFig. 2 Distribution of abnormal chromosomes in the aneuploid blastocystsbe obtained after transfer of embryos that have high
morphology score and are euploid.
In the present study, all embryos were biopsied at the
blastocyst stage. Many studies have proven that blasto-
cyst stage is the optimal stage to perform biopsies for
PGS, which produces higher implantation rates and pro-
vides more reliable aneuploidy results than cleavage stage
embryos [13, 14, 26]. Biopsy at blastocyst stage does not
result in a loss of inner cell mass and would not affect
subsequent fetal development, so it is less harmful to em-
bryo development [14, 15]. Furthermore, blastocyst biopsy
can acquire multiple TE cells [27], thus the results are
more accurate.
It has been repeatedly reported that more than half of
all morphologically normal blastocysts in women >35 years
old are aneuploid [7, 8, 12], and more than 50 % of first-
trimester spontaneous abortions are chromosomal aneu-
ploid [28]. So by doing PGS, euploid embryos can be
selected for transfer, thus implantation rates can be im-
proved, and miscarriages and trisomy offspring loss can be
reduced [11, 12].
As for the prevalence of aneuploidy and degree of
chromosome anomalies in the cryopreserved/warmed
blastocysts, it would appear that there was not muchdetected by TE biopsy and DNA microarray
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cysts. In the present study, we found that the overall an-
euploidy rate was 40.7 %, which was similar to that in
our previous report with fresh blastocyst aCGH [8].
However, direct comparison is difficult because patients’
populations are different between studies. Another simi-
lar result was the degree of chromosome anomalies in
the aneuploid embryos. In the previous study with fresh
blastocysts, it was found that 62.3 % of aneuploid blasto-
cysts had single chromosome errors [8], while the rate
was 65.6 % in the present study with frozen/warmed
blastocysts. Also, it was found that chromosomes 21 and
22 were two of the most frequent chromosome abnor-
malities in the aneuploid blastocysts in the fresh blasto-
cyst [8] as well as in the frozen/warmed blastocysts
(current study). Again, although the comparison is diffi-
cult between studies, the results may suggest that the
prevalence of aneuploidy in fresh blastocysts and frozen
blastocysts would be similar and cryopreservation/warming
may not increase chromosome abnormalities in human
blastocysts.
In the present study, our goal was limited to examine
the feasibility of biopsy of cryopreserved blastocyst for
PGS. We did not compare the outcome between PGS
and non-PGS cases, so the necessity of PGS on all previ-
ous IVF failures is still debatable as other factors (not only
embryo ploidy) also affect embryo implantation, such as
endometrium preparation and transfer itself. All IVF
failures cannot be attributed to embryonic aneuploidy. As
indicated in two recent review papers [29, 30], chromo-
somal mosaicism may cause incorrect embryo screening,
especially diploid-aneuploid mosaicism, which is the most
common chromosome mosaic in human embryos [29],
thus some screened “abnormal” embryos may have nor-
mal inner cell mass [8, 31]. Transfer of these kinds of
embryos may produce normal healthy babies. Indeed,
recently, Greco et al. reported that transfer of mosaic an-
euploid blastocysts can result in a high healthy live birth
rate (33 %) [32]. In this report, some of the embryos trans-
ferred had two chromosomal abnormalities [32]. One of
our patients also had a healthy baby after transfer of a
screened embryo, but this pregnancy had a mosaic pla-
centa although PGS showed it was a euploid [33]. These
results indicate that mosaic embryos can produce healthy
babies. As suggested by Liu et al., if all embryos are aneu-
ploidy in an IVF cycle, a second biopsy may be necessary
to find a transferrable embryo [8]. However, according to
Greco et al.’s report [32], transfer of these “aneuploid’
embryos after additional consents were signed by the pa-
tients may be practical without a second biopsy that may
cause more damages to embryos. Therefore, a careful
discussion and decision with patients should be necessary
if the patients do not have a normal embryo for transfer
after PGS.It has been reported that PGS can also improve clinical
outcome in young patients, especially when eSET is ap-
plied [10]. In our previous study, we did not find signifi-
cant increase in either clinical pregnancy or embryo
implantation when blastocysts from donated eggs were
screened and transferred, especially when two blastocysts
were transferred. As suggested by these authors, unre-
stricted clinical application of current PGS (either aCGH
or NGS) should be avoided [30, 31, 34].
In the present study, we found that 65.6 % of aneuploid
samples had single chromosomal error. If diploid-aneuploid
mosaic rate is high in these embryos as indicated in the
previous study (59 %) [29], it would be possible that
transfer of these embryos can produce normal preg-
nancy and result in healthy live births as reported by
Greco et al. [32]. Thus it must be careful to make the
decision to transfer, cryopreserve or discard these em-
bryos. As hypothesized by Greco et al. [32], the extent
and type of mosaicism may affect the IVF success rate,
and additional studies with large sample size are neces-
sary to test this hypothesis.Conclusions
From the present study, we conclude that frozen blastocysts
can be warmed and biopsied for aneuploidy screening. The
normal euploid blastocysts can be transferred within 24 h
after warming, and embryo implantation should not be
impaired by the procedures. Also, the prevalence of
aneuploidy in human blastocysts does not increase after
blastocysts are cryopreserved and warmed, suggesting that
current blastocysts vitrification and warming methods are
safe. As thousands of human embryos have been cryopre-
served without PGS, it may be necessary to perform biopsy
and PGS if the patients had repeated previous implantation
failures, miscarriages, and/or are of advanced maternal age.
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